Patents Assigned to XOMA
  • Method of treating chronic cardiac disease
    Patent number: 6509317
    Abstract: New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: January 21, 2003
    Assignees: Board of Regents, the University of Texas System, Xoma Technology Ltd.
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Methods for recombinant peptide production
    Patent number: 6500648
    Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: December 31, 2002
    Assignee: Xoma Technology, Ltd.
    Inventors: Marc D. Better, Patrick D. Gavit
  • Method for killing gram-negative bacteria with biologically active peptides from functional domains of bacterial/permeability-increasing protein
    Patent number: 6495516
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: December 17, 2002
    Assignee: Xoma Technology Ltd.
    Inventor: Roger G. Little, II
  • Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
    Patent number: 6482796
    Abstract: Improved therapeutic uses for N-terminal BPI protein products are described in patients that have BPI-reactive anti-neutrophil cytoplasmic antibodies.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: November 19, 2002
    Assignee: Xoma Corporation
    Inventor: Stephen Fitzhugh Carroll
  • Production of chimeric antibodies with specificity to human tumor antigens
    Patent number: 6461824
    Abstract: The invention is directed to chimeric immunoglobulins that recognize a human tumor antigen bound by antibody, ING-2, ING-3, ING-4 or KM10, the production of such chimeric immunoglobulins, and their use.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 8, 2002
    Assignee: Xoma Technology Ltd.
    Inventors: Marc D. Better, Arnold H. Horwitz, Randy R. Robinson, Shau-Ping Lei, Changtung Paul Chang
  • Identification of novel antimicrobial agents using membrane potential indicator dyes
    Patent number: 6455271
    Abstract: Novel screening methods for identifying antimicrobial agents involving use of membrane potential indicator dyes are provided.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: September 24, 2002
    Assignee: XOMA Technology, Ltd
    Inventors: Roger G. Little, II, Susan Abrahamson, Peter Wong
  • Method for quantifying LBP in body fluids
    Publication number: 20020127622
    Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.
    Type: Application
    Filed: November 26, 2001
    Publication date: September 12, 2002
    Applicant: XOMA Corporation
    Inventors: Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-Kuen Ma
  • Methods of treating conditions associated with corneal injury
    Publication number: 20020128191
    Abstract: The present invention provides methods of treating a subject suffering from adverse effects, complications or conditions, associated with or resulting from a corneal injury including, corneal infection or ulceration, by topical administration of suitable ophthalmic preparations of bactericidal/permeability-increasing (BPI) protein products.
    Type: Application
    Filed: August 27, 2001
    Publication date: September 12, 2002
    Applicant: XOMA Corporation
    Inventor: Patrick J. Scannon
  • Uses of lipopolysaccharide binding protein
    Publication number: 20020119930
    Abstract: Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin.
    Type: Application
    Filed: October 23, 2001
    Publication date: August 29, 2002
    Applicant: XOMA Corporation
    Inventors: Russell L. Dedrick, Stephen F. Carroll
  • Anti-protozoan methods and materials
    Patent number: 6440936
    Abstract: The present invention relates to methods for treating protozoan infections comprising administering to a subject suffering from protozoan infection, a bacteriocidal/permeability-inducing (BPI) protein product.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: August 27, 2002
    Assignee: Xoma Corporation
    Inventor: Lewis H. Lambert, Jr.
  • Identification of novel antimicrobial agents using metabolic oxidation-reduction indicator dyes
    Patent number: 6436660
    Abstract: Novel screening methods for identifying antimicrobial agents involving use of metabolic oxidation-reduction indicator dyes are provided.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: August 20, 2002
    Assignee: XOMA Technology Ltd.
    Inventor: Roger G. Little, II
  • Stable bactericidal permeability-increasing protein products and pharmaceutical compositions containing the same
    Patent number: 6433140
    Abstract: Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and state homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and in sequelae.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: August 13, 2002
    Assignee: XOMA Corporation
    Inventors: Georgia Theofan, Arnold Horwitz, David Burke, Manik Baltaian, Lynn Grinna
  • Therapeutic uses of BPI protein products for human meningococcemia
    Publication number: 20020103114
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Application
    Filed: November 30, 2000
    Publication date: August 1, 2002
    Applicant: XOMA Corporation and The Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Treatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
    Publication number: 20020103118
    Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.
    Type: Application
    Filed: February 13, 2001
    Publication date: August 1, 2002
    Applicant: XOMA Corporation
    Inventor: Lewis H. Lambert
  • Therapeutic derivative compounds derived from domain II of bactericidal/permeability-increasing protein
    Patent number: 6423825
    Abstract: The present invention relates generally to small derivatized peptide-based constructs and their therapeutic uses. The sequences of these derivatized peptide-based constructs are based on a reverse subsequence derived from Domain II of bactericidal/permeability-increasing protein (BPI).
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: July 23, 2002
    Assignee: Xoma Technology Ltd.
    Inventors: Roger G. Little, II, Jong-Jye Lin, J. G. Kinyua Gikonyo
  • Human therapeutic uses of BPI Protein products
    Publication number: 20020094952
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Application
    Filed: December 8, 2000
    Publication date: July 18, 2002
    Applicant: XOMA Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J.H. van Deventer, Marijke A.M. von der Mohlen, Nancy Wedel
  • Therapeutic uses of bactericidal/permeability increasing (BPI) protein products
    Publication number: 20020090368
    Abstract: The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.
    Type: Application
    Filed: August 27, 2001
    Publication date: July 11, 2002
    Applicant: XOMA Corporation
    Inventor: Roger G. Little
  • Anti-fungal peptides
    Publication number: 20020077298
    Abstract: The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and therapeutic uses of such peptides.
    Type: Application
    Filed: June 14, 2001
    Publication date: June 20, 2002
    Applicant: XOMA Corporation
    Inventors: Roger G. Little, Edward Lim, Mitchell B. Fadem
  • Therapeutic uses of BPI protein products in BPI-deficient humans
    Patent number: 6376465
    Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: April 23, 2002
    Assignee: XOMA Technology Ltd.,
    Inventor: Ofer Levy
  • Agents and methods for inhibiting F1/F0 ATPase
    Patent number: 6376211
    Abstract: Novel methods of identifying antimicrobial and anti-proliferative agents and therapeutic uses are provided.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: April 23, 2002
    Assignee: XOMA Technology Ltd.
    Inventors: Roger G. Little, II, Susan Abrahamson